answered for us at bottom of 4c. very soon.and they have dropped a 'new srtategic' direction on us... and for once no mention of the ongoing sale, and proving up their berst in class product with data.These guys are unbelivable
Webinar: What investors should know about what it takes for ASX-listed companies to get medical developments to market